Radius Health Shares Information about its Drug RAD011, Upcoming Study in New Fact Sheet

January 24, 2021 -- Radius Health, Inc. recently unveiled a detailed fact sheet about its drug RAD011, a synthetic cannabidiol oral solution, which is being studied as a possible treatment for hyperphagia and related behaviors in Prader-Willi syndrome. The fact sheet also gives a description of Radius Health's upcoming SCOUT-015 clinical trial. According to Radius Health, the SCOUT-015 clinical study will be a "global randomized, double-blind, placebo-controlled study in PWS with around 200 patients, and a seamless phase 2/3 design to allow for evaluation of multiple dose groups and Intent-To-Treat efficacy analysis with both Phase 2 and Phase 3 cohorts."

Currently, Radius Health is in the process of recruiting sites for the SCOUT-015 clinical trial and is not yet recruiting patients. PWSA | USA will continue to provide updates on the status of the SCOUT-015 study and the progress of RAD011.

You can download the RAD011 Fact Sheet by clicking here.

More information about Radius and RAD011 can be found at

Share this!

Scroll to top